Our key figures
Our revenue was CHF 241.2 million, a decrease of 2.8% (decrease 6.1% organically), compared with H1 2023. We delivered an adjusted EBITDA margin of 19.1% and free cash flow of CHF 7.6 million.
Share of revenue by market segment
H1 2024
Share of revenue by market segment
H1 2023
Key figures
January 1 – June 30
|
millions of CHF |
|
2024 |
|
% of revenue |
|
+/–% change |
|
2023 |
|
% of revenue |
|
Revenue |
|
241.2 |
|
100.0% |
|
–2.8% |
|
248.1 |
|
100.0% |
|
Organic revenue growth 1) |
|
|
|
|
|
–6.1% |
|
|
|
|
|
Gross profit |
|
80.6 |
|
33.4% |
|
–1.7% |
|
82.0 |
|
33.1% |
|
Operating income (EBIT) |
|
12.9 |
|
5.3% |
|
–11.0% |
|
14.5 |
|
5.8% |
|
EBITDA |
|
41.9 |
|
17.4% |
|
4.5% |
|
40.0 |
|
16.1% |
|
Adjusted EBITDA |
|
46.0 |
|
19.1% |
|
–7.4% |
|
49.7 |
|
20.0% |
|
Net income attributable to shareholders of medmix Ltd |
|
5.2 |
|
2.1% |
|
–29.2% |
|
7.3 |
|
2.9% |
|
Adjusted net income |
|
18.2 |
|
7.5% |
|
–24.0% |
|
23.9 |
|
9.7% |
|
Adjusted diluted earnings per share, attributable to a shareholder of medmix Ltd (in CHF) |
|
0.12 |
|
|
|
–78.6% |
|
0.58 |
|
|
|
Free cash flow (FCF) |
|
7.6 |
|
|
|
n/a |
|
–4.9 |
|
|
|
Adjusted operating net cash flow (adjusted ONCF) |
|
23.9 |
|
|
|
77.1% |
|
13.5 |
|
|
|
Capital expenditure, net (capex, net) |
|
17.1 |
|
|
|
–51.2% |
|
35.1 |
|
|
|
Net debt as of June 30 / December 31 |
|
223.2 |
|
|
|
1.9% |
|
219.0 |
|
|
|
Net debt adjusted EBITDA ratio as of June 30 / December 31 2) |
|
2.50 |
|
|
|
6.1% |
|
2.35 |
|
|
|
Employees (number of full-time equivalents) as of June 30 / December 31 |
|
2’695 |
|
|
|
1.4% |
|
2’658 |
|
|
1) Adjusted for currency effects.
2) Adjusted EBITDA for the last 12 months
Our Key figures
revenue in H1 2024
adjusted EBITDA margin
free cash flow generated in H1 2024